Laura Shawver Sells 14,772 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 14,772 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $13.75, for a total transaction of $203,115.00. Following the completion of the sale, the director now directly owns 210,346 shares in the company, valued at approximately $2,892,257.50. This trade represents a 6.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Laura Shawver also recently made the following trade(s):

• On Monday, December 2nd, Laura Shawver sold 97,244 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $13.56, for a total transaction of $1,318,628.64.

ARS Pharmaceuticals Stock Performance

ARS Pharmaceuticals stock opened at $14.00 on Friday. The company has a market capitalization of $1.36 billion, a P/E ratio of -27.45 and a beta of 0.88. ARS Pharmaceuticals, Inc. has a fifty-two week low of $5.01 and a fifty-two week high of $18.51. The stock has a 50-day simple moving average of $14.81 and a 200-day simple moving average of $12.17.

Analysts Set New Price Targets

SPRY has been the subject of a number of analyst reports. Raymond James upgraded shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and boosted their target price for the stock from $18.00 to $22.00 in a research note on Tuesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 price objective on shares of ARS Pharmaceuticals in a report on Tuesday, October 8th. William Blair upgraded ARS Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Leerink Partners increased their price target on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research note on Friday, September 20th. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $24.00.

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SPRY. Barclays PLC increased its holdings in shares of ARS Pharmaceuticals by 189.7% in the 3rd quarter. Barclays PLC now owns 111,666 shares of the company’s stock valued at $1,618,000 after acquiring an additional 73,127 shares during the period. Geode Capital Management LLC increased its stake in ARS Pharmaceuticals by 3.3% in the third quarter. Geode Capital Management LLC now owns 1,234,805 shares of the company’s stock valued at $17,909,000 after purchasing an additional 38,927 shares during the period. XTX Topco Ltd purchased a new stake in shares of ARS Pharmaceuticals in the third quarter valued at about $250,000. Wellington Management Group LLP boosted its stake in shares of ARS Pharmaceuticals by 38.9% during the third quarter. Wellington Management Group LLP now owns 162,335 shares of the company’s stock worth $2,354,000 after buying an additional 45,452 shares during the period. Finally, Wexford Capital LP purchased a new position in shares of ARS Pharmaceuticals during the third quarter worth about $3,601,000. Hedge funds and other institutional investors own 68.16% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.